{"id":"benlysta","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"10%","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Bronchitis","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Depression","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Migraine","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Cystitis","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Leukopenia","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Gastroenteritis viral","drugRate":"3%","severity":"common","organSystem":""}],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Serious infections","drugRate":"6%","severity":"serious"},{"effect":"Infusion reactions","drugRate":"1.6%","severity":"serious"},{"effect":"Lupus nephritis","drugRate":"0.7%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1789843","moleculeType":"Antibody"},"aliases":["Belimumab","belimumab"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Benlysta","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:17:49.574925+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:17:55.188626+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Benlysta","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:17:55.466113+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tumor necrosis factor ligand superfamily member 13B inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:56.485488+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1789843/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:56.154601+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"2fa3c528-1777-4628-8a55-a69dae2381a3","title":"BENLYSTA (BELIMUMAB) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION BENLYSTA (BELIMUMAB) SOLUTION [GLAXOSMITHKLINE LLC]"},"ecosystem":[],"mechanism":{"target":"Tumor necrosis factor ligand superfamily member 13B"},"_scrapedAt":"2026-03-28T03:22:47.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2024,"annualRevenue":1200,"revenueSource":"GSK AR 2024","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:17:57.837222+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Systemic lupus erythematosus","diseaseId":"systemic-lupus-erythematosus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04097561","phase":"PHASE1","title":"Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-01-13","conditions":"Idiopathic CD4 Lymphopenia","enrollment":20},{"nctId":"NCT06527872","phase":"","title":"Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-10-04","conditions":"Lupus Nephritis","enrollment":300},{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT01729455","phase":"","title":"Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-21","conditions":"Systemic Lupus Erythematosus","enrollment":3138},{"nctId":"NCT06576271","phase":"PHASE1","title":"A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-02","conditions":"Systemic Lupus Erythematosus","enrollment":142},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT06572384","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-11","conditions":"Lung Diseases, Interstitial","enrollment":440},{"nctId":"NCT06381453","phase":"PHASE2","title":"Belimumab in Autoimmune Hepatitis","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-12-11","conditions":"Autoimmune Hepatitis","enrollment":48},{"nctId":"NCT01649765","phase":"PHASE2","title":"Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-07","conditions":"Systemic Lupus Erythematosus","enrollment":93},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT07053137","phase":"","title":"A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yipeng Liu","startDate":"2025-11-30","conditions":"Systemic Lupus Erythematosus, Telitacicept, Belimumab","enrollment":180},{"nctId":"NCT07069972","phase":"","title":"A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.","status":"NOT_YET_RECRUITING","sponsor":"Yipeng Liu","startDate":"2026-02-01","conditions":"Systemic Lupus Erythematosus","enrollment":180},{"nctId":"NCT07031674","phase":"","title":"Comparing Efficacy and Safety of Telitacicept and Belimumab in Lupus Nephritis: A Retrospective Multicenter Cohort Study.","status":"COMPLETED","sponsor":"Yipeng Liu","startDate":"2025-10-01","conditions":"Lupus Nephritis, Belimumab","enrollment":56},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT03370263","phase":"","title":"BENLYSTA® Special Drug Use Investigation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-01-15","conditions":"Systemic Lupus Erythematosus","enrollment":1514},{"nctId":"NCT05878717","phase":"PHASE2, PHASE3","title":"A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2023-09-13","conditions":"Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic","enrollment":300},{"nctId":"NCT06716606","phase":"PHASE3","title":"A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-12-12","conditions":"Connective Tissue Diseases","enrollment":514},{"nctId":"NCT06411249","phase":"PHASE4","title":"A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-06-06","conditions":"Systemic Lupus Erythematosus","enrollment":350},{"nctId":"NCT05917288","phase":"PHASE1","title":"A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-07-07","conditions":"Systemic Lupus Erythematosus","enrollment":16},{"nctId":"NCT07225387","phase":"PHASE4","title":"Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial","status":"RECRUITING","sponsor":"NephroNet, Inc.","startDate":"2024-10-01","conditions":"Lupus Nephritis","enrollment":30},{"nctId":"NCT04179032","phase":"PHASE2","title":"Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2019-11-28","conditions":"Systemic Lupus Erythematosus","enrollment":25},{"nctId":"NCT07056621","phase":"","title":"Does Belimumab Modify the Natural History of SLE? A Propensity Score-matched, Real-world Study","status":"RECRUITING","sponsor":"Biomedical Research Foundation, Academy of Athens","startDate":"2025-06-30","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":684},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT04908865","phase":"PHASE4","title":"Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-21","conditions":"Systemic Lupus Erythematosus","enrollment":67},{"nctId":"NCT01532310","phase":"","title":"Belimumab (BENLYSTA®) Pregnancy Registry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-16","conditions":"Systemic Lupus Erythematosus","enrollment":77},{"nctId":"NCT04515719","phase":"PHASE4","title":"Efficacy and Safety of Belimumab in SLE Patients","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2021-03-10","conditions":"Systemic Lupus Erythematosus","enrollment":231},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT04611971","phase":"PHASE1","title":"A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-27","conditions":"Healthy","enrollment":13},{"nctId":"NCT06747312","phase":"PHASE2","title":"Effect of Belimumab on Antibody Titers in Primary APS Patients","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-04-01","conditions":"Antiphospholipid Syndrome (APS)","enrollment":20},{"nctId":"NCT05069051","phase":"PHASE2","title":"Belimumab in Patients with Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2022-01-19","conditions":"Chronic Lymphoid Leukemia in Relapse","enrollment":120},{"nctId":"NCT03747159","phase":"PHASE3","title":"Synergetic B-cell Immunomodulation in SLE - 2nd Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2018-10-01","conditions":"Lupus Erythematosus, Systemic","enrollment":70},{"nctId":"NCT05154734","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders","status":"COMPLETED","sponsor":"Tianjin Medical University General Hospital","startDate":"2021-12-12","conditions":"NMO Spectrum Disorder","enrollment":14},{"nctId":"NCT01705977","phase":"PHASE4","title":"Belimumab Assessment of Safety in SLE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-27","conditions":"Systemic Lupus Erythematosus","enrollment":4019},{"nctId":"NCT04629144","phase":"PHASE2","title":"Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-10-20","conditions":"Vasculitis, Cryoglobulinemia","enrollment":48},{"nctId":"NCT04570306","phase":"","title":"Transcriptional and Immune Parameters of Response to Belimumab","status":"COMPLETED","sponsor":"Biomedical Research Foundation, Academy of Athens","startDate":"2020-12-16","conditions":"Systemic Lupus Erythematosus","enrollment":85},{"nctId":"NCT06410833","phase":"PHASE4","title":"Belimumab After Rituximab in Resistant Primary Juvenile SS","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-03-09","conditions":"Sjogren's Syndrome, Pediatric ALL","enrollment":15},{"nctId":"NCT06327724","phase":"","title":"Belimumab in SLE Synovial Inflammation and Lymph Nodes","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-09-01","conditions":"Systemic Lupus Erythematosus","enrollment":15},{"nctId":"NCT03207958","phase":"PHASE1","title":"Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-05-16","conditions":"Graft Vs Host Disease, Graft-versus-host-disease","enrollment":10},{"nctId":"NCT03543839","phase":"PHASE4","title":"Trial of Belimumab in Early Lupus","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2020-09-15","conditions":"Lupus Erythematosus, Systemic, Lupus Erythematosus","enrollment":30},{"nctId":"NCT02347891","phase":"PHASE2, PHASE3","title":"Belimumab in Idiopathic Inflammatory Myositis","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2015-01","conditions":"Myositis","enrollment":17},{"nctId":"NCT04893161","phase":"PHASE4","title":"A Model About the Response of Belimumab in SLE","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-06-01","conditions":"Systemic Lupus Erythematosus","enrollment":72},{"nctId":"NCT05338190","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-14","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":132},{"nctId":"NCT03244059","phase":"PHASE2","title":"Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-08-09","conditions":"Chronic Obstructive Pulmonary Disease, Emphysema","enrollment":17},{"nctId":"NCT04447053","phase":"PHASE4","title":"Sequential Belimumab and T-cell Based Therapy in SLE","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2021-11-08","conditions":"Systemic Lupus Erythematosus","enrollment":80},{"nctId":"NCT05863936","phase":"PHASE3","title":"Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis","status":"UNKNOWN","sponsor":"Nanjing University School of Medicine","startDate":"2023-04-01","conditions":"Lupus Nephritis, Remission, Safety Issues","enrollment":15},{"nctId":"NCT04767698","phase":"PHASE2","title":"Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2021-10-01","conditions":"Multiple Sclerosis","enrollment":4},{"nctId":"NCT05604742","phase":"PHASE1, PHASE2","title":"Belimumab for Treatment of cGVHD Following Allo-HCT","status":"WITHDRAWN","sponsor":"xuna","startDate":"2022-01-01","conditions":"cGVHD","enrollment":""},{"nctId":"NCT05020782","phase":"PHASE2, PHASE3","title":"The BeLimumab Antiphospholipid Syndrome Trial (BLAST)","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2022-06-01","conditions":"Antiphospholipid Syndrome","enrollment":15},{"nctId":"NCT03591380","phase":"PHASE2","title":"CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2019-05-14","conditions":"Kidney Transplantation","enrollment":3},{"nctId":"NCT05659407","phase":"","title":"BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Cagliari","startDate":"2020-07-24","conditions":"Systemic Lupus Erythematosus, Rheumatoid Arthritis, BLyS Polymorphism","enrollment":60},{"nctId":"NCT05624437","phase":"","title":"BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Centre Hospitalier de Niort","startDate":"2021-11-19","conditions":"SLE (Systemic Lupus)","enrollment":33},{"nctId":"NCT05588830","phase":"","title":"The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-10-20","conditions":"Lupus Nephritis, Belimumab, Telitacicept","enrollment":60},{"nctId":"NCT05585671","phase":"","title":"Belimumab In Prevention of LN","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-06-01","conditions":"Whether Belimumab Could Reduce 2-year Risk of New-onset Lupus Nephritis","enrollment":48},{"nctId":"NCT04956484","phase":"PHASE4","title":"Belimumab In Early Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2021-09-01","conditions":"Lupus Erythematosus, Systemic","enrollment":16},{"nctId":"NCT01670565","phase":"PHASE2","title":"Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"Hospital for Special Surgery, New York","startDate":"2012-08","conditions":"Systemic Sclerosis","enrollment":20},{"nctId":"NCT05358652","phase":"","title":"Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Renal Biopsy","status":"UNKNOWN","sponsor":"Fundacin Biomedica Galicia Sur","startDate":"2021-10-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":60},{"nctId":"NCT05262686","phase":"PHASE3","title":"Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-04-01","conditions":"Systemic Lupus Erythematosus","enrollment":10},{"nctId":"NCT03967925","phase":"PHASE2","title":"Rituximab and Belimumab Combination Therapy in PR3 Vasculitis","status":"UNKNOWN","sponsor":"Rachel Jones","startDate":"2019-02-01","conditions":"ANCA Associated Vasculitis, Granulomatosis With Polyangiitis","enrollment":31},{"nctId":"NCT01632241","phase":"PHASE4","title":"Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2013-02-19","conditions":"Systemic Lupus Erythematosus","enrollment":503},{"nctId":"NCT02631538","phase":"PHASE2","title":"Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02-17","conditions":"Sjogren's Syndrome","enrollment":86},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT04660565","phase":"PHASE4","title":"Belimumab Treatment for IgG4-related Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-01","conditions":"IgG4-related Disease","enrollment":60},{"nctId":"NCT04136145","phase":"PHASE1","title":"Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-28","conditions":"Systemic Lupus Erythematosus","enrollment":36},{"nctId":"NCT04671706","phase":"","title":"Belimumab in Patients With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Fundación Española de Medicina","startDate":"2021-01","conditions":"Systemic Lupus Erythematosus","enrollment":3000},{"nctId":"NCT02260934","phase":"PHASE2","title":"Rituximab and Belimumab for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-09","conditions":"Lupus Nephritis","enrollment":43},{"nctId":"NCT02880852","phase":"PHASE1","title":"Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-23","conditions":"Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT01597622","phase":"PHASE3","title":"BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-06-11","conditions":"Systemic Lupus Erythematosus","enrollment":142},{"nctId":"NCT03154385","phase":"NA","title":"Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-03-13","conditions":"Immune Thrombocytopenia","enrollment":15},{"nctId":"NCT02119156","phase":"PHASE3","title":"Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-13","conditions":"Systemic Lupus Erythematosus","enrollment":80},{"nctId":"NCT00712933","phase":"PHASE3","title":"A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2008-05-30","conditions":"Systemic Lupus Erythematosus","enrollment":738},{"nctId":"NCT01345253","phase":"PHASE3","title":"GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-05-23","conditions":"Systemic Lupus Erythematosus","enrollment":709},{"nctId":"NCT00583362","phase":"PHASE2","title":"A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2005-05-04","conditions":"Systemic Lupus Erythematosus","enrollment":298},{"nctId":"NCT02500251","phase":"PHASE1, PHASE2","title":"Belimumab Impacting Transplant Eligibility","status":"COMPLETED","sponsor":"E. Steve Woodle","startDate":"2015-06","conditions":"Renal Transplant Rejection","enrollment":11},{"nctId":"NCT03919643","phase":"","title":"BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2019-05-01","conditions":"Systemic Lupus Erythematosus, BAFF Polymorphism","enrollment":200},{"nctId":"NCT02284984","phase":"PHASE2","title":"Synergetic B-cell Immodulation in SLE","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2014-03","conditions":"Lupus Erythematosus, Systemic","enrollment":16},{"nctId":"NCT03501420","phase":"","title":"Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-13","conditions":"Sjogren's Syndrome","enrollment":2223},{"nctId":"NCT01597492","phase":"PHASE4","title":"A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-05-31","conditions":"Systemic Lupus Erythematosus","enrollment":79},{"nctId":"NCT01484496","phase":"PHASE3","title":"A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2011-11-16","conditions":"Systemic Lupus Erythematosus","enrollment":839},{"nctId":"NCT01663623","phase":"PHASE3","title":"Belimumab in Remission of VASculitis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2013-03-20","conditions":"Vasculitis","enrollment":106},{"nctId":"NCT02124798","phase":"PHASE2","title":"A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-05-20","conditions":"Systemic Lupus Erythematosus","enrollment":95},{"nctId":"NCT03125486","phase":"","title":"Compassionate Use for Subcutaneous (SC) Belimumab","status":"NO_LONGER_AVAILABLE","sponsor":"GlaxoSmithKline","startDate":"","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT02270970","phase":"PHASE4","title":"Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy","status":"UNKNOWN","sponsor":"Oklahoma Medical Research Foundation","startDate":"2014-10","conditions":"Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT01610492","phase":"PHASE2","title":"A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-07-01","conditions":"Glomerulonephritis, Membranous","enrollment":14},{"nctId":"NCT01516450","phase":"PHASE1","title":"Japanese phase1 Study of Belimumab (IV vs SC)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-26","conditions":"Systemic Lupus Erythematosus","enrollment":16},{"nctId":"NCT01381536","phase":"PHASE1","title":"Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-20","conditions":"Systemic Lupus Erythematosus","enrollment":12},{"nctId":"NCT01025193","phase":"PHASE2","title":"Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2010-02","conditions":"Desensitization","enrollment":8},{"nctId":"NCT01894360","phase":"PHASE1","title":"A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-14","conditions":"Systemic Lupus Erythematosus","enrollment":81},{"nctId":"NCT01536379","phase":"PHASE2","title":"A Study of Belimumab in the Prevention of Kidney Transplant Rejection","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-09","conditions":"Transplantation, Organ","enrollment":30},{"nctId":"NCT01762852","phase":"PHASE2","title":"Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Glomerulonephritis, Membranous","enrollment":""},{"nctId":"NCT01480596","phase":"PHASE2","title":"The Evaluation of Belimumab in Myasthenia Gravis (MG)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04","conditions":"Myasthaenia Gravis","enrollment":40},{"nctId":"NCT00410384","phase":"PHASE3","title":"A Study of Belimumab in Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2006-12","conditions":"Systemic Lupus Erythematosus","enrollment":819},{"nctId":"NCT00424476","phase":"PHASE3","title":"A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2007-05","conditions":"Systemic Lupus Erythematosus","enrollment":865},{"nctId":"NCT00724867","phase":"PHASE3","title":"A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2008-08","conditions":"Systemic Lupus Erythematosus","enrollment":268},{"nctId":"NCT01440361","phase":"PHASE2","title":"A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2013-03","conditions":"Purpura, Thrombocytopaenic, Idiopathic","enrollment":""},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT00071812","phase":"PHASE2","title":"A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2003-12","conditions":"Arthritis, Rheumatoid","enrollment":283},{"nctId":"NCT01583530","phase":"PHASE1","title":"Study of Belimumab Administered Subcutaneously to Healthy Subjects","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2011-02","conditions":"Healthy","enrollment":118},{"nctId":"NCT00583557","phase":"PHASE2","title":"A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01","status":"TERMINATED","sponsor":"Human Genome Sciences Inc.","startDate":"2005-01","conditions":"Rheumatoid Arthritis","enrollment":155},{"nctId":"NCT00732940","phase":"PHASE2","title":"Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Human Genome Sciences Inc.","startDate":"2008-10","conditions":"Systemic Lupus Erythematosus","enrollment":56},{"nctId":"NCT00071487","phase":"PHASE2","title":"Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2003-10","conditions":"Lupus Erythematosus, Systemic","enrollment":449}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1789843"},"formularyStatus":[],"_approvalHistory":[{"date":"20180622","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20230215","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20250620","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20120330","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20190913","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20240516","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20201216","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20170118","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20200924","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20161202","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20131213","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20140403","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20220726","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20200117","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20240209","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20110309","type":"ORIG","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20190426","type":"SUPPL","sponsor":"HUMAN GENOME SCIENCES INC.","applicationNumber":"BLA125370"},{"date":"20190426","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20190913","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20240516","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20220726","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20201216","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20200117","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20180622","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20240209","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20250620","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20170720","type":"ORIG","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"},{"date":"20230215","type":"SUPPL","sponsor":"GLAXOSMITHKLINE LLC","applicationNumber":"BLA761043"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":56,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:57:47.695629+00","biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Benlysta","genericName":"Benlysta","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":15,"withResults":4},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:17:57.837222+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}